Google Seeks Delay on Data-Sharing Order as It Appeals Landmark Antitrust Ruling 
China’s AI Models Narrow the Gap With the West, Says Google DeepMind CEO 
BYD Shares Rise in Hong Kong on Reports of Battery Supply Talks With Ford 
Micron to Buy Powerchip Fab for $1.8 Billion, Shares Surge Nearly 10% 
Sanofi Gains China Approval for Myqorzo and Redemplo, Strengthening Rare Disease Portfolio 
Anthropic Appoints Former Microsoft Executive Irina Ghose to Lead India Expansion 
Baidu Shares Rise in Hong Kong After Apollo Go Robotaxi Launch in Abu Dhabi 
Tesla Revives Dojo Supercomputer Project With AI5 Chip at the Core 
Toyota Industries Buyout Faces Resistance as Elliott Rejects Higher Offer 
One Percent Rule Checklist For Safer Forex Trading Risk 
Proposed Rio Tinto–Glencore Merger Faces China Regulatory Hurdles and Asset Sale Pressure 
TikTok Expands AI Age-Detection Technology Across Europe Amid Rising Regulatory Pressure 
xAI Restricts Grok Image Editing After Sexualized AI Images Trigger Global Scrutiny 
U.S. Transportation Board Sends Union Pacific–Norfolk Southern Merger Back for Revision 
TSMC Shares Hit Record High as AI Chip Demand Fuels Strong Q4 Earnings 
China Halts Shipments of Nvidia H200 AI Chips, Forcing Suppliers to Pause Production 
Bristol Myers Squibb Co would buy MyoKardia Inc for about $13 billion to bolster its portfolio of heart disease treatments and shield itself from competition posed by Merck & Co’s Keytruda on its for its cancer immunotherapy, Opdivo.
The deal gives Bristol Myers, which acquired pharmaceutical company Celgene last year for $74 billion, access to Myokardia’s lead heart drug candidate with blockbuster potential, mavacamten.
According to David Nierengarten, a Wedbush analyst, mavacamten is expected to be a “multi-billion dollar asset” as sales estimates for the treatment of obstructive hypertrophic cardiomyopathy (HCM) is expected to reach about $2.5 billion by 2026.
Hypertrophic cardiomyopathy is estimated to affect one in every 500 people globally.
MyoKardia expects to submit a marketing application to the US health regulator for mavacamten as an obstructive HCM treatment in the first quarter of 2021.
Bristol Myers' portfolio of heart drugs includes blood thinner Eliquis, which made up about 21 percent of the company’s total sales in its latest reported quarter.
